Medical Research Council (MRC), The Gambia Unit, Banjul, The Gambia.
PLoS One. 2012;7(2):e31050. doi: 10.1371/journal.pone.0031050. Epub 2012 Feb 20.
A 9-valent pneumococcal conjugate vaccine (PCV-9), given in a 3-dose schedule, protected Gambian children against pneumococcal disease and reduced nasopharyngeal carriage of pneumococci of vaccine serotypes. We have studied the effect of a booster or delayed primary dose of 7-valent conjugate vaccine (PCV-7) on antibody and nasopharyngeal carriage of pneumococci 3-4 years after primary vaccination.
METHODOLOGY/PRINCIPAL FINDINGS: We recruited a subsample of children who had received 3 doses of either PCV-9 or placebo (controls) into this follow-up study. Pre- and post- PCV-7 pneumococcal antibody concentrations to the 9 serotypes in PCV-9 and nasopharyngeal carriage of pneumococci were determined before and at intervals up to 18 months post-PCV-7. We enrolled 282 children at a median age of 45 months (range, 38-52 months); 138 had received 3 doses of PCV-9 in infancy and 144 were controls. Before receiving PCV-7, a high proportion of children had antibody concentrations >0.35 µg/mL to most of the serotypes in PCV-9 (average of 75% in the PCV-9 and 66% in the control group respectively). The geometric mean antibody concentrations in the vaccinated group were significantly higher compared to controls for serotypes 6B, 14, and 23F. Antibody concentrations were significantly increased to serotypes in the PCV-7 vaccine both 6-8 weeks and 16-18 months after PCV-7. Antibodies to serotypes 6B, 9V and 23F were higher in the PCV-9 group than in the control group 6-8 weeks after PCV-7, but only the 6B difference was sustained at 16-18 months. There was no significant difference in nasopharyngeal carriage between the two groups.
CONCLUSIONS/SIGNIFICANCE: Pneumococcal antibody concentrations in Gambian children were high 34-48 months after a 3-dose primary infant vaccination series of PCV-9 for serotypes other than serotypes 1 and 18C, and were significantly higher than in control children for 3 of the 9 serotypes. Antibody concentrations increased after PCV-7 and remained raised for at least 18 months.
在 3 剂方案中使用 9 价肺炎球菌结合疫苗(PCV-9),可保护冈比亚儿童免受肺炎球菌疾病的侵害,并降低疫苗血清型的鼻咽肺炎球菌携带率。我们研究了在初次接种后 3-4 年,7 价结合疫苗(PCV-7)的加强针或延迟初次剂量对抗体和鼻咽肺炎球菌携带率的影响。
方法/主要发现:我们从接受过 3 剂 PCV-9 或安慰剂(对照组)的儿童中招募了一个亚样本进行这项随访研究。在接种 PCV-7 前后及之后的 18 个月内,测定了对 PCV-9 中的 9 种血清型的前 PCV-7 肺炎球菌抗体浓度和鼻咽肺炎球菌携带率。我们在中位数为 45 个月(范围,38-52 个月)时招募了 282 名儿童;其中 138 名儿童在婴儿期接受了 3 剂 PCV-9,144 名是对照组。在接受 PCV-7 之前,大多数儿童对 PCV-9 中的大多数血清型的抗体浓度>0.35 µg/mL(PCV-9 组平均为 75%,对照组为 66%)。接种组的几何平均抗体浓度明显高于对照组,分别为血清型 6B、14 和 23F。在接种 PCV-7 后 6-8 周和 16-18 个月,对 PCV-7 疫苗中的血清型的抗体浓度显著增加。在接种 PCV-7 后 6-8 周,PCV-9 组的血清型 6B、9V 和 23F 的抗体水平高于对照组,但只有 6B 的差异在 16-18 个月时仍持续存在。两组之间鼻咽携带率无显著差异。
结论/意义:在冈比亚儿童接受 3 剂 PCV-9 作为基础婴儿免疫接种系列后 34-48 个月,除血清型 1 和 18C 以外的血清型的肺炎球菌抗体浓度较高,并且对于 9 种血清型中的 3 种,其抗体浓度明显高于对照组。接种 PCV-7 后抗体浓度增加,并至少持续升高 18 个月。